Citigroup’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-4
Closed -$1K 6585
2022
Q2
$1K Sell
4
-68
-94% -$14.3K ﹤0.01% 6158
2022
Q1
$21K Sell
72
-23
-24% -$8.73K ﹤0.01% 5132
2021
Q4
$50K Buy
+95
New +$68.2K ﹤0.01% 5067
2021
Q2
Sell
-7
Closed -$9K 6527
2021
Q1
$9K Buy
7
+4
+133% +$5.51K ﹤0.01% 5729
2020
Q4
$4K Buy
3
+2
+200% +$2.93K ﹤0.01% 7170
2020
Q3
$1K Buy
+1
New +$2.26K ﹤0.01% 7412

Other funds holding BIOR

Citigroup's BIOR Position: Q3 2022 in Review

Citigroup sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q3 2022, closing a stake of 4 shares — an estimated $1K sold.

Citigroup first reported a position in BIOR in Q3 2020 and held it in 6 quarters. The position peaked at $50K in Q4 2021. 44 funds tracked by Wall St. Rank hold BIOR as of Q3 2022.

  • Citigroup reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 4 Biora Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1K.
  • Citigroup first reported a position in Biora Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
  • Citigroup's Biora Therapeutics, Inc. Common Stock position peaked at $50K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.